Revolution Medicines (NASDAQ:RVMD) will host a webcast on Sunday, May 31, 2026, at 7:00 PM ET to discuss results from its Phase 3 RASolute 302 clinical trial.
The webcast will cover data on daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The company characterized the trial results as positive.
Data will be presented during the Plenary Session at the 2026 American Society of Clinical Oncology Annual Meeting before the webcast.
A replay will be available on the company's website for at least 14 days after the live broadcast.
Revolution Medicines develops targeted therapies for RAS-addicted cancers. Its pipeline includes daraxonrasib, elironrasib, zoldonrasib, and RMC-5127.
